Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors. Its technologies are designed to be applied in a target and modality agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL), and T cell receptor (TCR) therapies. The company develops Gen-R and Epi-R technology platforms to develop a multi-modality product.